Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Sponsor
SecuraBio (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT02605694
Collaborator
(none)
0
Enrollment
1
Location
2
Arms
11
Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Phase II study to evaluate the efficacy and safety of DR vs R-CHOP in subjects with relapsed/refractory FL

Condition or DiseaseIntervention/TreatmentPhase
Phase 2

Detailed Description

This is a phase 2, randomized, two-arm, open-label study designed to evaluate the efficacy and safety of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Study Start Date :
Dec 1, 2015
Actual Primary Completion Date :
Nov 1, 2016
Actual Study Completion Date :
Nov 1, 2016

Arms and Interventions

ArmIntervention/Treatment
Experimental: Arm 1

Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).

Drug: Duvelisib
25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
Other Names:
  • IPI-145
  • Drug: Rituximab
    375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
    Other Names:
  • MabThera
  • Rituxan
  • Active Comparator: Arm 2

    R-CHOP will be administered as follows: IV infusion on Day 1 of Cycles 1-6 (21-day cycles) Cyclophosphamide (750 mg/m2) Doxorubicin hydrochloride (50 mg/m2) Vincristine sulfate (1.4 mg/m2) (2 mg maximum) Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles) Prednisone (100 mg) will be administered.

    Drug: Rituximab
    375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
    Other Names:
  • MabThera
  • Rituxan
  • Drug: R-CHOP
    IV infusion on Day 1 of Cycles 1-6 (21-day cycles) Cyclophosphamide (750 mg/m2) Doxorubicin hydrochloride (50 mg/m2) Vincristine sulfate (1.4 mg/m2) (2 mg maximum) Rituximab (375 mg/m2)
    Other Names:
  • Rituximab
  • CHOP
  • Drug: Prednisone
    100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
    Other Names:
  • Deltasone
  • Outcome Measures

    Primary Outcome Measures

    1. Progression Free Survival (PFS) [Time from randomization to documented disease progression, or death due to any cause, whatever comes first, assessed up to approximately 44 months.]

      Progression Free Survival (PFS), defined according to the revised International Working Group (IWG) criteria as assessed by the Independent Review Committee (IRC)

    Secondary Outcome Measures

    1. Complete Response Rate (CRR) [Every 3-6 Cycles (Cycles 1-6 are 21-days; after Cycle 7 are 28-days) from randomization until first documented progression. Subjects will be evaluated for progression or the primary analysis of PFS, whichever occurs first.]

      Complete Response Rate (CRR) with complete response defined according to the revised IWG criteria as assessed by the IRC

    2. Overall Response Rate (ORR) [Every 3-6 Cycles (Cycles 1-6 are 21-days; after Cycle 7 are 28-days) from randomization until first documented progression or the primary analysis of PFS, whichever occurs first.]

      ORR defined as best response of complete response (CR) or partial response/remission (PR), according to the revised IWG criteria as assessed by the IRC

    3. Overall Survival [Every 6 months until the primary analysis for PFS or 3 years from randomization, whichever occurs later.]

    4. Safety (Treatment Emergent Adverse Events (TEAEs) and changes in safety laboratory values as assessed by NCI-CTCAE, version 4.03) [Continuous from informed consent until 30 days from last dose]

      Adverse events (AEs) and abnormal laboratory values

    5. Pharmacokinetics: Evaluate the Duvelisib concentration in plasma sample [Cycle 1 Day 15, Cycle 2 Day 1 and 15 (Cycles 1-6 are 21-day cycles)]

      Evaluate the Duvelisib concentration in plasma sample

    6. Duration of Response [Every 3-6 Cycles (Cycles 1-6 are 21-days; after Cycle 7 are 28-days) from the first documented response to first documented progression or death, whichever occurs first.]

      DOR defined as the time from the first documented response to the first documentation of progressive disease (PD) according to the revised IWG criteria or death due to any cause (for subjects with CR or PR only)

    7. Pharmacokinetics: Evaluate IPI-656 (metabolite) concentration in plasma sample [Cycle 1 Day 15, Cycle 2 Day 1 and 15 (Cycles 1-6 are 21-day cycles)]

      Evaluate IPI-656 (metabolite) concentration in plasma sample

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Diagnosis of FL: Grade 1, 2, or 3a

    2. Progressed within 24 months of initiating an alkylator-based chemotherapy regimen given as either first- or second-line therapy; single-agent chlorambucil therapy does not fulfill this requirement Note: subjects must have received at least 2 cycles of alkylator-based chemotherapy to be eligible

    3. Previously received rituximab, either as single agent or as part of any combination regimen, and also meet one of the following requirements:

    4. Progressed within 24 months of initiating alkylator-based chemotherapy in the first line and received no additional anticancer therapy

    5. Progressed within 24 months of initiating alkylator-based chemotherapy in the first line and subsequently progressed within 24 months of receiving any second-line treatment and received no additional anticancer therapy

    6. Progressed within 24 months of initiating alkylator-based chemotherapy in the second line and received no additional anticancer therapy

    7. Appropriate to receive R-CHOP

    8. At least 1 measurable disease lesion > 1.5 cm in at least one dimension by computed tomography (CT), CT-PET, or magnetic resonance imaging (MRI)

    9. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (corresponds to Karnofsky Performance Status [(KPS) ≥60%])

    10. For women of childbearing potential (WCBP): negative serum β human chorionic gonadotropin (βhCG) pregnancy test within 1 week before first treatment (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women >55 years of age)

    Exclusion Criteria:
    1. Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3B FL

    2. Received ≥ 3 previous anticancer regimens prior to enrollment

    3. Received prior R-CHOP therapy

    4. Previous receipt of any anthracycline

    5. Contraindication to any of the individual components of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone) Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of the study drugs

    6. Received prior allogeneic transplant

    7. Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor

    8. History of tuberculosis treatment within the two years prior to randomization

    9. History of chronic liver disease, veno-occlusive disease, alcohol abuse

    10. Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids >20 mg of prednisone (or equivalent) QD

    11. Ongoing treatment for systemic bacterial, fungal, or viral infection at screening

    12. Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A (CYP3A)

    13. Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening

    14. Concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix

    15. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or a pacemaker within the last 6 months prior to screening

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1MiamiFloridaUnited States33133

    Sponsors and Collaborators

    • SecuraBio

    Investigators

    • Study Chair: Hagop Youssoufian, MD, Verastem, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    SecuraBio
    ClinicalTrials.gov Identifier:
    NCT02605694
    Other Study ID Numbers:
    • IPI-145-21
    • 2015-004729-15
    First Posted:
    Nov 16, 2015
    Last Update Posted:
    Mar 17, 2021
    Last Verified:
    Mar 1, 2021
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 17, 2021